14th week of 2022 patent applcation highlights part 7 |
Patent application number | Title | Published |
20220105025 | Hair and Scalp Treatment Solution - This present invention relates to a hair and scalp treatment and strengthening composition. The hair and scalp treatment and strengthening composition comprises quantities of an aloe vera gel, turmeric root, ginger root, petroleum jelly, grape seed oil, coconut oil, peppermint oil, rosemary oil, a grave sea oil, and vanilla fragrance oil. The hair and scalp treatment and strengthening composition assists in reducing alopecia, treating over processed hair and hair loss, as well as stimulating new hair growth. | 2022-04-07 |
20220105026 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A JAK INHIBITOR AND DEVICES - This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK inhibitor. | 2022-04-07 |
20220105027 | MEDROXYPROGESTERONE ACETATE INJECTABLE COMPOSITIONS AND METHODS OF USE - The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 260 mg/ml to 440 mg/ml medroxyprogesterone acetate, about 0.6 mg/ml to 1.5 mg/ml docusate sodium and, polyethylene glycol. Methods of using these compositions are also described. | 2022-04-07 |
20220105028 | METHOD FOR IMPROVING STORAGE STABILITY - A submucosal injection material whose quality deterioration during a storage period is prevented is provided. It is a submucosal injection material, which contains hyaluronic acid, and to which a dye is added. | 2022-04-07 |
20220105029 | BIODEGRADABLE CHITOSAN MICRONEEDLE PATCH FOR TRANSDERMAL DELIVERY FOR LIVESTOCK PAIN MANAGEMENT - Disclosed herein is a microneedle array comprising a substrate and a plurality of microneedles extending therefrom, wherein the microneedles comprise a biodegradable polymer and an effective amount of an analgesic or an anti-inflammatory therapeutic agent. Methods of using and making the microneedle array are also disclosed. | 2022-04-07 |
20220105030 | INTRANASAL DELIVERY OF DIHYDROERGOTAMINE BY PRECISION OLFACTORY DEVICE - Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (C | 2022-04-07 |
20220105031 | METHOD FOR ADMINISTERING LIPOSOMAL COMPOSITION - The invention pertains to liposomes containing an oil-in-water emulsion of a selected combination of at least ten different essential plant oils produced with phospholipids found in human membranes and methods for treating respiratory diseases, disorders or conditions by administering the liposomes into the nose and respiratory system. | 2022-04-07 |
20220105032 | BEVERAGE UNIT AND METHOD TO PROVIDE THE BEVERAGE UNIT - A beverage unit and method to provide the beverage unit, are disclosed herein. The beverage unit comprising: at least 1 gram of d-mannose; at least 6 ounces of liquid, wherein the at least 1 gram of d-mannose is dissolved and combined with the 6 ounces of liquid to create a solution; and a single-serving liquid package, wherein the solution is stored in the liquid package for single-use consumption. | 2022-04-07 |
20220105033 | STABLE SOLID DISPERSION OF A B-RAF KINASE DIMER INHIBITOR, METHODS OF PREPARATION, AND USES THEREFOR - Disclosed herein is a physically stable solid dispersion comprising Compound 1, i.e., the B-RAF kinase dimer inhibitor 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa [b]benzofuran-1 yl)-3-(2, 4, 5-trifluorophenyl) urea and a specific stabilizing polymer, the method for preparing the same, and the uses of the solid dispersion. Also disclosed herein is the crystalline form of Compound 1. | 2022-04-07 |
20220105034 | MICROBUBBLE DISPERSION SYSTEM STABILIZED WITH POLYDOPAMINE NANOPARTICLES FOR HIGHLY-EFFICIENT INTRAVENOUS OXYGEN SUPPLY AND METHOD FOR PREPARING THE SAME - The present application discloses a microbubble dispersion system stabilized with polydopamine nanoparticles for highly-efficient intravenous oxygen supply and a method for preparing the same. The method includes: dissolving dopamine, chitosan quaternary ammonium salt and amino-rich polymer in water, adjusting the pH to be alkaline, and then introducing oxygen into the solution; under the strong shear force of a homogenizer, oxygen oxidizing dopamine, and the obtained polydopamine nanoparticles adhering to the interface of oxygen microbubbles during polymerization, forming a compact shell layer of polydopamine particles; finally, adding glutaraldehyde to solidify the shell layer of polydopamine particles adhered to the interface of microbubbles, and obtaining oxygen microbubbles stably dispersed in water by filtration, washing and redispersion. The oxygen microbubbles stabilized with polydopamine nanoparticles have excellent biocompatibility, can realize rapid and efficient delivery of oxygen, and thus have an important application value in the field of highly-efficient intravenous oxygen supply. | 2022-04-07 |
20220105035 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF - Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or | 2022-04-07 |
20220105036 | NANO-CARRIER TOPICAL COMPOSITION WITH VITAMIN D3 - The nano-carrier topical composition with Vitamin D3 includes Vitamin D3, Span 40, Span 80, cholesterol, ethanol, almond oil, glycerin, water, aloe vera gel, and sodium hydroxide. The nano-carrier topical composition with Vitamin D3 forms an alkaline composition having nano-carriers with an average diameter of 50.8 μm. The composition can be transported through the stratum corneum so that the composition may be used for fulfilling daily requirements for Vitamin D3, treatment of bone conditions, such as rickets and osteomalacia, and supportive therapy in osteopenia and osteoporosis. Optionally, the composition may include perfume and/or one or more preservatives (e.g., a carbomer, methyl paraben, EDTA, or the like), or other additives that do not affect the active ingredients. The composition is preferably formulated as a cream or emulsion wherein the nano-carriers are niosomes. | 2022-04-07 |
20220105037 | SERIAL FILTRATION TO GENERATE SMALL CHOLESTEROLCONTAINING LIPOSOMES - The present invention provides methods and systems for producing liposomes by filtration. The methods include passing a heated lipid suspension through a filter assembly comprising two or more filters connected in series, wherein an orifice is disposed between adjacent filters. The methods and systems can produce liposomes having an average diameter that is less than half the diameter of the filter pores. Further, the methods and systems can produce liposomes with <100 nm average diameter, even when the liposomes comprise at least 30% sterol. | 2022-04-07 |
20220105038 | Microparticles comprising PCL and uses thereof - The invention relates to a process for preparing PCL-comprising microparticles, to microparticles obtainable by said process, to gel hence obtained and to several uses of the gel such as for the preparation of a medicament for treating a skin abnormality or disfigurement, and/or for controlling bladder function and/or controlling gastric reflux and/or for treating erectile dysfunction and/or for treating vocal cords. The gel may also be used for cosmetic applications. | 2022-04-07 |
20220105039 | Use of Nanoparticles to Stabilize and Preserve the Bioactivity of Proteins and Peptides - Provided herein are methods of making and using storage-stable protein-coated articles that retain activity after drying. Also provided herein are kits comprising storage-stable protein-coated articles that retain activity after drying. | 2022-04-07 |
20220105040 | MULTI-PARTICULATE PHARMACEUTICAL COMPOSITION OF QUETIAPINE - The present invention discloses an extended release multi-particulate sprinkle composition comprising a plurality of discrete units, each discrete unit comprising quetiapine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. | 2022-04-07 |
20220105041 | METHOD FOR MANUFACTURING A SOLID ADMINISTRATION FORM AND SOLID ADMINISTRATION - For manufacturing a solid administration form comprising at least one active pharmaceutical ingredient, a flowable but setting composite material comprising the at least one active pharmaceutical ingredient is added together and set to generate the solid administration form. The flowable composite material is liquefied and delivered to a discharge unit. Small portions of liquefied composite material are intermittently discharged through an outlet into a setting unit. The flowable composite material comprises a polymer and at least one active pharmaceutical ingredient dispersed or dissolved within the polymer. The small portions are droplets and the solid administration form is generated by adding droplets that stick together before or during the setting of the liquefied composite material. An average diameter of the droplets can be less than 350 μm. There can be a void space between at least some small portions, resulting in a porous structure of the solid administration form. | 2022-04-07 |
20220105042 | POLYMERIC IMPLANTS WITH HIGH DRUG LOADING AND LONG-ACTING DRUG RELEASE AND METHODS OF MAKING THE SAME - Disclosed herein are polymeric implants and controlled release drug delivery systems to provide high drug loading and long-acting drug release. Provided herein are methods for making the same. Methods of administering pharmacologically active agents via the disclosed polymeric implants and controlled release drug delivery systems are also provided. | 2022-04-07 |
20220105043 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to solid pharmaceutical dosage forms comprising an extended release core comprising metformin hydrochloride and one or two immediate release coatings comprising linagliptin and/or empagliflozin. | 2022-04-07 |
20220105044 | MODIFIED RELEASE COMPOSITIONS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE - Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions. | 2022-04-07 |
20220105045 | PULLULAN EMPTY HARD CAPSULE AND PREPARATION METHOD THEREFOR | 2022-04-07 |
20220105046 | COMPOSITION FOR PROMOTING WOUND HEALING AND PREPARING METHOD THEREOF - The present disclosure relates to a composition sustainable-releasing hydrogen sulfide for promoting wound healing and the method for preparing the same. The composition for promoting wound healing comprises a carrier and a plurality of hydrogen sulfide sustained releasing microspheres, wherein the hydrogen sulfide sustained releasing microspheres comprise a hydrophobic polymer, a surfactant and sodium hydrosulfide. | 2022-04-07 |
20220105047 | MICROCAPSULE COMPOSITION USING ALGINATE GEL, AND METHOD FOR PRODUCING SAME - The present invention relates to a microcapsule composition in which polydopamine-coated calcium carbonate microspheres are encapsulated by forming an alginate gel on the surface of a spheroid conjugated thereto, and a method of preparing the same, and it is confirmed that according to the method of preparing the microcapsule, the drug or physiologically active material was individually microencapsulated by gradually forming an alginate gel on the surface of the spheroid containing the drug or physiologically active material, a drug or a bioactive material is placed in the center of a capsule in a very simple way, and a capsule of a very small size can be manufactured in a short time compared to the conventional encapsulation method by adjusting the size of the capsule. | 2022-04-07 |
20220105048 | Low Temperature Process For Preparing Silicon Oxide Coated Pharmaceuticals - A method of preparing a pharmaceutical composition having a drug-containing core enclosed by one or more silicon oxide materials is provided. The method entails alternating exposing the particles to gaseous or vaporous SiCl | 2022-04-07 |
20220105049 | COMPOSITIONS COMPRISING ELECTROHYDRODYNAMICALLY OBTAINED FIBRES FOR ADMINISTRATION OF SPECIFIC DOSAGES OF AN ACTIVE SUBSTANCE TO SKIN OR MUCOSA - The present invention relates to electrospun fibers comprising | 2022-04-07 |
20220105050 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS - The present disclosure pertains to the use of propofol prodrugs, pharmaceutically acceptable salts of propofol prodrugs, or mixtures thereof, to treat migraine. | 2022-04-07 |
20220105051 | COMPOUNDS FOR INCREASING MHC-I EXPRESSION AND MODULATING HISTONE DEACETYLASE ACTIVITY - An object of the present invention is to provide a compound for modulating expression of Major Histocompatibility Complex Class I (MHC-1) and/or TAP-1, in eukaryotic cells. In certain aspects, the compound is a curcuphenol, a terpene or a cannabinoid. Also provided are a composition that comprises the compound and methods of use thereof, for instance, for augmenting an immune response involving MHC-1 CTL, treating cancer, or treating a disease associated with histone acetylation abnormalities. | 2022-04-07 |
20220105052 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN - The invention relates to the compounds or their pharmaceutically acceptable polymorphs, solvates, enantiomers, stereoisomers, and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV, and formula XV and the methods for treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, or parenteral administration, or as a lozenge, spray, oral solution, buccal mucosal layer tablet, syrup or injection. Such compositions may be used to treat chronic pain. | 2022-04-07 |
20220105053 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ACIDOSIS - The present invention relates to a pharmaceutical composition for preventing or treating acidosis. The pharmaceutical composition has a remarkable effect in decreasing the concentration of acid accumulated in an organism and thus is expected to be widely used in the fields of medicine and health. | 2022-04-07 |
20220105054 | ABSORPTION ENHANCER OF CINNAMIC ACID DERIVATIVE - The present invention provides an absorption enhancer of a cinnamic acid derivative containing curcumin as an active ingredient, the cinnamic acid derivative is at least one selected from the group consisting of a compound represented by formula (1): | 2022-04-07 |
20220105055 | ABUSE-DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE - Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose. | 2022-04-07 |
20220105056 | N-Acetylcysteine Amide (NACA) and (2R,2R')-3,3' disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) for the Prevention and Treatment of Radiation Dermatitis and Skin Lightening, Skin Whitening and Skin Improvement - The present invention includes a method for the use of N-acetylcysteine (NAC), N-acetylcysteine amide (NAC A) or (2R,2R′)-3,3′-disulfanediylbis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation dermatitis, radiation damage to the skin, xeroderma pigmentosa or protect patients with xeroderma pigmentosa from skin damage caused by exposure to the sun or other radiation, bioweapons, chemical burns, heat burns, contact damage caused by friction, contact dermatitis, hypersensitivity reactions and skin wrinkles and dehydration, skin lightening, skin whitening, and/or skin improvement in a human that comprises administering to the human a therapeutically effective amount of NAC, NACA or diNACA. | 2022-04-07 |
20220105057 | METHODS OF TREATMENT - This disclosure features compounds and compositions that are useful in methods of treating coronavirus infections (e.g., useful in methods of treating COVID-19) in a subject in need thereof. The methods include administering to the subject niclosamide compounds (or pharmaceutically acceptable salts and/or co-crystals thereof, e.g., niclosamide). In some embodiments, the niclosamide compounds have one or more properties that include, but are not limited to: a particular purity or a particular particle size. In an aspect, the niclosamide compounds described herein (e.g., niclosamide) can form part of compositions, dosage forms (e.g., unit dosage forms), and the like, which are suitable for respiratory administration (e.g., via inhalation and/or intranasally). In another aspect, the niclosamide compounds described herein (e.g., niclosamide) can form part of compositions, dosage forms (e.g., unit dosage forms), and the like, which are suitable for administration to the GI tract (e.g., orally or rectally such as via enema)). | 2022-04-07 |
20220105058 | USE OF 3-O-SULFAMATE-16,16-DIMETHYL-D-HOMOEQUILENIN TO TREAT ONCOLOGICAL DISEASES - The invention relates to the field of medicine and to the chemical and pharmacological industry, and concerns agents for the treatment of cancer. 3-O-Sulfamate 16,16-dimethyl-D-homoequilenin is proposed as an anti-cancer agent in monotherapy and adjuvant therapy of oncological diseases such as hepatocellular carcinoma, gastric carcinoma, lung cancer, chronic myelogenous leukemia, and breast cancer including triple negative breast cancer. The new compound has not any uterotropic activity in animals and does not influence on endometrium. | 2022-04-07 |
20220105059 | METHOD OF TREATING OR PREVENTING NEURODEGENERATION - The invention relates to a compound which is effective in inhibiting the function of the TRPM4 ion channel and the use of such compound in treating or preventing a neurodegenerative disease, such as Multiple Sclerosis, Parkinson's disease, Alzheimer's disease, or amyotrophic lateral sclerosis, in a subject. The invention also provides a pharmaceutical composition comprising a TRPM4 inhibitory compound. The invention further relates to in vitro methods for identifying pharmaceutically active compounds that are useful for treating or preventing a neurodegenerative disease. | 2022-04-07 |
20220105060 | POULTICE - The present invention provides a gel patch having a paste layer on a support, wherein the paste layer comprising ketoprofen or a pharmaceutically acceptable salt thereof, propylene glycol, 1-menthol, and water, wherein the mass of propylene glycol in the paste layer is 3-fold the mass of ketoprofen or less, and wherein the content of 1-menthol based on a total mass of the paste layer is 0.1 to 0.5 mass %. | 2022-04-07 |
20220105061 | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY INSUFFICIENCY - The present invention relates to compositions of chemical chaperone and methods of using the same to treat endoplasmic reticulum stress including pulmonary or cardiac insufficiency in diseases such as osteogenesis imperfecta. | 2022-04-07 |
20220105062 | TRANSDERMAL PENETRANT FORMULATIONS - Disclosed herein is a transdermal delivery formulation for transdermal delivery of an active agent through the skin, nail or hair follicle of a subject, wherein the formulation comprises a) a transdermal delivery formulation in an amount less than about 60% w/w, comprising i. one or more phosphatides, ii. glucose, and iii. one or more fatty acids; and b) water in an amount less than about 50% w/w. | 2022-04-07 |
20220105063 | Composition for Treatment and / or Prevention of Infectious Hoof Diseases - The current invention provides a composition for use in the topical treatment and/or prevention of infectious hoof diseases in an animal, wherein composition comprises a medium-chain fatty acid (MCFA) fraction comprising one or more MCFAs and/or derivatives thereof. In a second aspect, the invention provides a method for disinfecting the hoofs of an animal comprising the step of topically administering a composition comprising an MCFA fraction to said animal, wherein said MCFA fraction comprises one or more MCFAs and/or derivatives thereof. In a final aspect, the invention provides a disinfectant composition comprising an MCFA fraction and acarboxylic acid (CA) fraction, wherein said MCFA fraction comprises MCFAs and/or derivatives thereof, and said CA fraction comprises one or more carboxylic acids. | 2022-04-07 |
20220105064 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 2022-04-07 |
20220105065 | METHOD OF TREATING PATIENTS WITH A FACTOR Xa INHIBITOR, ASPIRIN, AND VERAPAMIL - The present disclosure in various embodiments teaches methods of treating patients in need of treatment with a Factor Xa inhibitor, and who are also concomitantly administered aspirin and verapamil. | 2022-04-07 |
20220105066 | Antidotes to Cyanide Poisoning - The present application provides, inter alia, a compound of Formula (I): | 2022-04-07 |
20220105067 | Pharmaceutical Compositions of Dimethyl Fumarate - Pharmaceutical compositions and dosage forms of dimethyl fumarate containing low levels of certain impurities are disclosed. | 2022-04-07 |
20220105068 | PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS AND USES THEREFOR - The present disclosures provides new technologies for treatment and/or prevention of certain dermatological conditions, specifically including graying hair. Among other things, the present disclosure provides an insight that plasminogen activator inhibitor-1 (PAI-1) inhibitors may be useful in the treatment and/or prevention of certain dermatological conditions, and in particular in treatment and/or prevention of graying hair. | 2022-04-07 |
20220105069 | METHODS FOR TREATING BRAIN METASTASIS - The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin. | 2022-04-07 |
20220105070 | TOPICAL FORMULATIONS HAVING CANNABINOID - Disclosed are cannabinoid formulations and methods of use associated therewith. Specifically, disclosed are topical or transdermal formulations having a cannabinoid in combination with a phyto-compound excipient that facilitates absorption and bioavailability of the cannabinoid. | 2022-04-07 |
20220105071 | DETECTION AND TREATMENT OF DAUGHTER NUMBER VARIATIONS IN CANCER CELLS - The present disclosure provides in vitro methods for predicting a compound's ability to inhibit multinucleate cell production resulting from post-mitotic cell fusion during a process of Daughter Number Variation (DNV) in mitosis. Compounds identified by this method can be used in cancer treatment, either alone or in combination with other known cancer drugs. The present invention also provides methods of personalized cancer treatment for a patient having a malignant tumor. | 2022-04-07 |
20220105072 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPLICATIONS COMPRISING NOVEL CHRYSIN DERIVATIVE COMPOUND AS ACTIVE INGREDIENT - Provided are methods and compositions for the prevention and treatment of diabetes complications. The methods include administration of pharmaceutical compounds containing a novel chrysin derivative compound as an active ingredient. More specifically, the pharmaceutical compositions inhibit the formation of an advanced glycation end product (AGE) thereby preventing or treating diabetes complications. | 2022-04-07 |
20220105073 | TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSES IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIA - Friedreich ataxia (FRDA) is caused by a GAA repeat expansion in FXN gene that encodes a mitochondrial protein, frataxin, involved in iron sulfur complex (ISC) assembly. Frataxin deficiency results in abnormal ISC containing proteins, namely respiratory chain complex I-III and aconitases and accumulation of iron in brain and heart of patients. Here, the inventors show that FRDA fibroblasts are unable to limit iron uptake inducing a massive cytosolic iron accumulation and to a lesser extent in mitochondria. The inventors also observed increased transferrin receptor (TfR1) steady state levels and membrane TfR1 accumulation that they ascribed to impaired post-translational modification by palmitoylation as well as delayed transferrin recycling. Finally, the inventors showed that artesunate, dichloroacetate and Coenzyme-A improved TfR1 palmitoylation and thus represent candidate molecules for the treatment of patients with Friedreich ataxia. Thus the present invention relates to methods of treating Friedreich ataxia (FRDA) as well as to methods of predicting whether a patient suffering from FRDA will achieve a therapeutic response. | 2022-04-07 |
20220105074 | ORAL ADMINISTRATION OF MELANIN FOR PROTECTION AGAINST RADIATION - Methods and compositions are provided for alleviating and/or preventing one or more side effects associated with exposure to radiation in a subject exposed to radiation or at risk for exposure to radiation comprising oral administration to the subject of an amount of an edible source of melanin effective to alleviate a side effect associated with radiation. | 2022-04-07 |
20220105075 | CHEMICAL COMPOSITIONS AND METHODS FOR ENHANCING TRANSDERMAL DELIVERY OF THERAPEUTIC AGENTS - The present application discloses chemical compositions and methods for enhancing the transdermal permeation of therapeutic agents through skin. The chemical compositions and methods of the invention can include combinations of a first fatty acid having about 14 or more carbon atoms and a second fatty acid having about 10 or less carbon atoms. These compositions are useful for the delivery of therapeutic agents, in particular hard to deliver drugs such as those that have fused rings, including ondansetron, and large drugs such as peptides. The compositions of the invention can be formulated as transdermal gels, lotions, creams, transdermal patches, sprays or mists. | 2022-04-07 |
20220105076 | Inhibitor for V-Atpase Activity, Antibacterial Agent, Medicine, Antibacterial Method and Screening Method - An inhibitor for Na | 2022-04-07 |
20220105077 | APPLICATION OF 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES IN ANTIVIRAL THERAPY - Related is application of 2,4,5-trisubstituted 1,2,4-triazolones in antiviral therapy, particularly related to use of a compound of formula I in the preparation a medicament, wherein the medicament is used to prevent and/or treat a disease associated with a virus. It is shown in vitro experiment that, the compound effectively inhibits viral infections, and shows low toxicity in some tests, | 2022-04-07 |
20220105078 | USES OF 4'-DESFERRITHIOCIN ANALOGS - Macular degeneration, closed head injury, stroke, irritable bowel disease, and reperfusion injury are all associated with biological injury due to reactive oxygen species, probably due to focal iron overload in many instances. The present invention provides methods and pharmaceutical compositions for treating these diseases and conditions using desferrithiocin analogs of Formula (I). In certain embodiments, the analogs include a poly ether moiety at the 4′-position of the phenyl ring of the compound. | 2022-04-07 |
20220105079 | Methods Of Treating Fabry Patients Having Renal Impairment - Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day. | 2022-04-07 |
20220105080 | PSEUDOMONAS STRAINS AND THEIR METABOLITES TO CONTROL FISH DISEASES - The present disclosure concerns methods of using novel bacterial strains of 0617-T307, 0917-T305, 0917-T306, 0917-T307, 0118-T319, 0318-T327, and 0418-T328, the cell broth and novel metabolites produced from the bacterial strains, that can inhibit the growth of a variety of fish pathogens. The methods include use of novel, potent antimicrobial metabolites produced from the strains corresponding to a compound having Formula (I): | 2022-04-07 |
20220105082 | NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS - There is provided pharmaceutical formulations that may be used topically comprising a leukotriene receptor antagonist, a salt or a solvate thereof. Particular leukotriene receptor antagonists that may be mentioned include montelukast styrene. The formulations find particular utility in direct topical administration for the treatment of inflammation, of inflammatory disorders and/or of condition characterized by inflammation, including wounds, burns, psoriasis, haemorrhoids, acne and atopic dermatitis. | 2022-04-07 |
20220105083 | USES OF COMPOUNDS HAVING ANTI-HSV-1 ACTIVITY - This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same in a subject comprising the step of contacting the subject with a composition comprising a quindoline (or similar) structure having significant anti-HSV activity. | 2022-04-07 |
20220105084 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA - This disclosure provides pharmaceutical compositions comprising dextromethorphan in combination with quinidine, and methods for treating agitation and/or aggression in subjects with dementia by administering such compositions. | 2022-04-07 |
20220105086 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-04-07 |
20220105087 | Increasing Drug Bioavailability In Naltrexone Therapy - Disclosed are compositions, uses, methods and kits for increasing drug bioavailability in a naltrexone therapy. | 2022-04-07 |
20220105088 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSON, ANXIETY, AND NEURODEGENERATIVE DISORDERS - Pharmaceutical compositions and methods for treating depression, anxiety, and neurodegenerative diseases and cognitive disorders, such as dementia and Alzheimer's disease, by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 2022-04-07 |
20220105089 | PROCESS FOR PREPARING ARIPIPRAZOLE ORAL SOLUBLE FILM - The present invention is directed to an aripiprazole oral soluble film and a preparation method thereof. The aripiprazole oral soluble film comprises 10-60% w/w of aripiprazole in a crystalline state and 30-95% w/w of one or more film-forming materials, wherein 90% of the aripiprazole particles have a size of ≤14.3 μm and are uniformly blended in the film without visible undispersed particles. The aripiprazole oral soluble film has excellent bioavailability, uniformity, stability, and palatability. The oral soluble film preparation is prepared by first grinding aripiprazole particles to have desired small particle sizes, then blending the aripiprazole particles with film forming materials in an aqueous solution to a uniform suspension, defoaming the suspension, and coating the suspension on a substrate and drying it to form a film. | 2022-04-07 |
20220105090 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE CONDITIONS - The present invention is directed to compositions for and methods for the treatment of presbyopia, irregular astigmatism, and/or refractive error comprising from about 0.1% to about 4.0% w/v of a muscarinic agonistand from about 0.001% to about 0.1% w/v brimonidine. | 2022-04-07 |
20220105091 | FUSED TRICYCLIC PYRAZOLO-DIHYDROPYRAZINYL-PYRIDONE COMPOUNDS AS ANTIVIRALS - The invention provides compounds of Formula (I) | 2022-04-07 |
20220105092 | METHODS FOR TREATING CHOLESTASIS - Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg/kg/day. | 2022-04-07 |
20220105093 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF - The present disclosure generally relates to pharmaceutical compositions and combinations comprising N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy) methyl)pyrimidin-2-yOmethanesulfonamideN-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl) propan-2-yl) phenoxy) methyl)pyrimidin-2-yl)methanesulfonamide or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, and a second therapeutically active agent, such as an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer. | 2022-04-07 |
20220105094 | Methods Of Treating Depression Using Orexin-2 Receptor Antagonists - The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R | 2022-04-07 |
20220105095 | COMPOSITE VITAMIN COMPOSITION PROMOTING GASTROINTESTINAL SYSTEM MOTILITY - Disclosed are composite compositions of B vitamins and C vitamins and the use of same in the preparation of a drug or health food for treating and/or preventing gastrointestinal conditions diseases related to deficiency of the gastrointestinal system motility. The composition comprises a vitamin B composition or an analogue or a derivative thereof and a vitamin C or an analogue or a derivative thereof. | 2022-04-07 |
20220105096 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION - The compound | 2022-04-07 |
20220105097 | METHODS OF TREATMENT OF MYELOPROLIFERATIVE NEOPLASM - Provided are methods and compositions for treating myeloproliferative neoplasms in patients carrying an IDH2 mutation and a JAK2 mutation. | 2022-04-07 |
20220105098 | EZH2 INHIBITORS FOR TREATING CANCER - The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer. | 2022-04-07 |
20220105099 | METHOD FOR THE DETECTION OF DRUG-INDUCED ORGAN OR TISSUE INJURY IN IMPDH INHIBITOR TREATED PATIENTS - The present disclosure concerns methods of detecting injury to a tissue and/or organ in a subject. In some aspects, the subject is the recipient of a transplant, such as a liver transplant. In some aspects, the subject is undergoing treatment with an immunosuppressant. In some aspects, the present disclosure concerns the identification of aberrant mitochondria in the subject to identify injury to the tissue and/or organ of the subject. Detecting aberrant mitochondria allows for remedial and/or corrective action to prevent or avoid significant injury. | 2022-04-07 |
20220105100 | SAFE BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENT - Disclosed herein are safe pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. Disclosed are compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s) and an effective amount of a penetration enhancement component comprising one or more penetration enhancer compound(s)/molecule(s), e.g., benzalkonium chloride, which detectably or significantly increases the penetration of API(s) of the composition. In aspects, the invention provides compositions comprising a brinzolamide compound in an amount of about 0.1 wt. %-10 wt. % of the composition, a brimonidine compound, e.g., brimonidine tartrate, in an amount of about 0.01 wt. %-0.5 wt. % of the composition, one or more borate-polyol complexes in an amount of about 0.5 wt. %-6 wt. % of the composition, and a penetration enhancement component comprising benzalkonium chloride, in, for example, an amount of about 0.005-0.02 wt. % of the composition. | 2022-04-07 |
20220105101 | EFFICIENT BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS - Disclosed herein are pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. In aspects, the invention provides compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s). In facets, compositions comprise a penetration enhancer component comprising one or more penetration enhancer compound(s)/molecule(s). In aspects, the invention provides compositions comprising effective amounts of brimonidine compound(s) and brinzolamide compound(s) capable of being administered once or twice daily for the treatment of elevated intraocular pressure, but which provide similar efficacy to a similar or substantially identical reference product requiring administration three times per day. In facets, the invention provides compositions capable of being administered at a frequency resulting in providing a lower total dose of both brinzolamide and brimonidine compound(s) to a recipient, but nonetheless are as or more effective in IOP control as such similar or substantially identical reference products. | 2022-04-07 |
20220105102 | METHODS OF EFFICIENTLY REDUCING INTRAOCULAR PRESSURE - Disclosed herein are pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. In aspects, the invention provides compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s). In facets, compositions comprise a penetration enhancer component comprising one or more penetration enhancer compound(s)/molecule(s). In aspects, the invention provides compositions comprising effective amounts of brimonidine compound(s) and brinzolamide compound(s) capable of being administered once or twice daily for the treatment of elevated intraocular pressure, but which provide similar efficacy to a similar or substantially identical reference product requiring administration three times per day. In facets, the invention provides compositions capable of being administered at a frequency resulting in providing a lower total dose of both brinzolamide and brimonidine compound(s) to a recipient, but nonetheless are as or more effective in IOP control as such similar or substantially identical reference products. | 2022-04-07 |
20220105103 | SAFE USE OF BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENT - Disclosed herein are safe pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. Disclosed are compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s) and an effective amount of a penetration enhancement component comprising one or more penetration enhancer compound(s)/molecule(s), e.g., benzalkonium chloride, which detectably or significantly increases the penetration of API(s) of the composition. In aspects, the invention provides compositions comprising a brinzolamide compound in an amount of about 0.1 wt. %-10 wt. % of the composition, a brimonidine compound, e.g., brimonidine tartrate, in an amount of about 0.01 wt. %-0.5 wt. % of the composition, one or more borate-polyol complexes in an amount of about 0.5 wt. %-6 wt. % of the composition, and a penetration enhancement component comprising benzalkonium chloride, in, for example, an amount of about 0.005-0.02 wt. % of the composition. | 2022-04-07 |
20220105104 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2022-04-07 |
20220105105 | NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA - Various embodiments relate to compounds, having structures according to Structure A or Structure B, as specified herein. The compounds according to various embodiments may inhibit NT5C2 nucleotidase. The compounds according to various embodiments may synergistically decrease cell viability of NT5C2 R367Q mutant lymphoblasts when used in combination with 6-mercaptopurine (6-MP) to treat a cancer. The cancer may be, but is not limited to, acute lymphoblastic leukemia. Various embodiments relate to a compositions that may include one or more compounds according to any embodiment described herein or a pharmaceutically acceptable salt or derivative thereof and a pharmaceutically acceptable carrier. Various embodiments relate to methods of treating cancer. The method may comprise administering a therapeutically effective amount of one or more compounds according to any embodiment described herein or a pharmaceutically acceptable salt or derivative thereof. | 2022-04-07 |
20220105106 | COMPOSITIONS AND METHODS RELATING TO USE OF AGONISTS OF ALPHA5-CONTAINING GABAA RECEPTORS - The invention provides methods and related compositions for preventing neurocognitive decline associated with chronic stress, age, and neurodegenerative diseases. The methods described here are based upon the use of alpha5-GABAA receptor agonists to slow or prevent deleterious morphological changes in dendrites of the hippocampus and prefrontal cortex, which eventually manifest in functional decline and the neurocognitive deficits. | 2022-04-07 |
20220105107 | BIOIDENTICAL PROGESTERONE CREAM INFUSED WITH NANOEMULSIFIED CBD - The present invention is a transdermal composition, for self-administering bioidentical hormone replacement and hormone balancing therapy and hormone balancing for both women and men, using a combination of progesterone and Cannabidiol (CBD) in various forms including nano-emulsified configurations. The compositions, which are topically applied by the user are trans dermally or topically delivered to the vascular system of the user in accordance with a dosage protocol established that will optimize the hormone levels of the user. Specific properties of CBD when combined with progesterone can provide an “entourage effect” that is produced from the synergistic interaction of the cannabinoids and progesterone in the user. The composition may also comprise various other excipients. | 2022-04-07 |
20220105109 | METHODS OF TREATING COVID-19 AND COMPOSITIONS THEREFOR - Methods and compositions for treating COVID-19 in humans, particularly for treating at least one respiratory symptom, are disclosed. The composition includes a therapeutically effective amount of acetylsalicylic acid (ASA), expected to be in the range of approximately 0.4-4.0 grams per day. The composition may also include a therapeutically effective amount of famotidine, expected to be in the range of approximately 10-160 milligrams per day. | 2022-04-07 |
20220105110 | COMPOSITION FOR THE TREATMENT OF COVID-19 - A formulation provides a unique synergistic composition for the treatment of the novel Coronavirus (COVID-19). Due to multiple mechanisms and synergy of action of the ingredients involved, using drug and nutrient therapy to support the body's natural immune response, it can provide a significant advantage to currently used therapies and may also be administered prophylactically. In its optimal embodiment the composition can be prepared in solid (tablet or capsule) or liquid form, containing Aspirin or any natural salicinoid, Phenylephrine, Promethazine, Vitamin D, Vitamin C, Niacinamide, Iodine Zinc and Selenium. | 2022-04-07 |
20220105111 | FOSPROPOFOL METHODS AND COMPOSITIONS - The present disclosure pertains to the use of fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof, to treat migraine. | 2022-04-07 |
20220105112 | Fospropofol Salts, Methods And Compositions - The present disclosure pertains to pharmaceutically acceptable salts of fospropofol and their use to treat migraine. | 2022-04-07 |
20220105113 | CYLODIMER OF DEHYDROSALICORTIN AND DERIVATIVES THEREOF ISOLATED FROM PLANT OF THE GENUS SALIX FOR USE IN CANCER THERAPY - Described herein are compounds comprising a dimer of dehydrosalicortin or a derivative, homologue, stereoisomer, prodrug or pharmaceutical salt thereof. In particular embodiments, the dimer is a result of a Diels-Alder reaction. Also described are compositions comprising the compounds and their use in treating disease. | 2022-04-07 |
20220105114 | METHODS FOR TREATING CHEMORESISTANT CANCER-INITIATING CELLS - The disclosure provides methods of treating cancer by selectively inhibiting p-S | 2022-04-07 |
20220105115 | PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE - Provided is a method of making a preliposomal Annamycin lyophilizate, the composition made by the method, and the use of the composition made thereby in the treatment of cancer. | 2022-04-07 |
20220105116 | METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN - Methods of reconstituting lyophilized Annamycin and methods of treating patients are described. | 2022-04-07 |
20220105117 | COMPOSITIONS COMPRISING NICOTINAMIDE RIBOSIDE AND A UROLITHIN - A composition comprising:
| 2022-04-07 |
20220105118 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF - The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein. | 2022-04-07 |
20220105119 | DELIVERY OF AEROSOLIZED MICROMOLAR COMPOSITION CONCENTRATIONS - Formulations and pressurized devices able to get Ivermectin concentrations in the micromolar range in the upper and lower respiratory tract and the oropharyngeal cavity are disclosed. The formulations and devices are used for the prevention or treatment of respiratory diseases caused by SARS CoV 2, such as pandemic COVID 19, and other viruses for which Ivermectin exerts viral inactivation at this concentration range. | 2022-04-07 |
20220105120 | COMPOSITIONS AND METHODS FOR INHIBITING INOSINE MONOPHOSPHATE DEHYDROGENASE - The invention provides compositions and methods for treating conditions in a subject by inhibiting inosine monophosphate dehydrogenase. The invention provides compositions and methods that provide periods of sustained inhibition of inosine monophosphate dehydrogenase followed by periods in which enzyme activity is not inhibited. The invention also provides methods that include monitoring inhibition of inosine monophosphate dehydrogenase via analysis of GTP levels. | 2022-04-07 |
20220105121 | COMPOSITIONS AND METHODS FOR INHIBITING INOSINE MONOPHOSPHATE DEHYDROGENASE - The invention provides compositions and methods for treating conditions in a subject by providing an inhibitor of inosine phosphate dehydrogenase that promotes decreased levels of guanosine triphosphate and/or increased levels of hypoxanthine. | 2022-04-07 |
20220105122 | THERAPEUTIC AND PROPHYLACTIC AGENT FOR GLIOMA, BRAIN TUMOR MALIGNANCY MARKER, BRAIN TUMOR PROGNOSTIC MARKER, METHOD FOR DETERMINING MALIGNANCY AND PROGNOSIS OF BRAIN TUMOR AND ANTIBODY INHIBITING TUMOR PROLIFERATION - A novel agent is for treating or preventing a glioma. A marker for malignancy of a brain tumor and a prognostic marker for a brain tumor can be used in a method for determining malignancy of a brain tumor and a method for determining a prognosis for a brain tumor patient. The agent for treating or preventing a glioma can include an HVEM inhibitor as an active ingredient. The marker for malignancy of a brain tumor and the prognostic marker for a brain tumor can each include an HVEM protein or an HVEM gene. The method for determining malignancy of a brain tumor and the method for determining a prognosis for a brain tumor patient can each include measuring an HVEM expression amount in a biological sample of a subject. | 2022-04-07 |
20220105123 | MICELLAR NANOPARTICLES AND USES THEREOF - The present disclosure includes cationic carrier units comprising (i) a water soluble polymer, (ii) a positively charged carrier, and (iii) an adjuvant moiety, wherein when the cationic carrier unit is mixed with an anionic payload (e.g., an antisense oligonucleotide) that electrostatically interacts with the cationic carrier unit, the resulting composition self-organizes into a micelle encapsulating the anionic payload in its core. The cationic carrier units can also comprise a tissue specific targeting moiety, which would be displayed on the surface of the micelle. The disclosure also includes micelles comprising the cationic carrier units of the disclosure, methods of manufacture of cationic carrier units and micelles, pharmaceutical compositions comprising the micelles, and also methods of treating diseases or conditions comprising administering the micelles to a subject in need thereof. | 2022-04-07 |
20220105124 | METHODS FOR TARGETED TREATMENT AND PREDICTION OF PATIENT SURVIVAL IN CANCER - Provided herein are methods of assessing, detecting, monitoring the presence, or monitoring progression of cancer in a subject, or assessing or predicting prognosis or survival of a subject having cancer. Also provided are methods of treating cancer based on an increase in the expression of one or more top master regulators of a cancer. | 2022-04-07 |
20220105125 | AGENT FOR IMPROVING OCULAR SUBJECTIVE SYMPTOMS AND METHOD THEREOF - Provided is an agent for proving human ocular subjective symptoms containing hyaluronic acid having an aminoalkyl cinnamate covalently bonded thereto. | 2022-04-07 |
20220105126 | COMPOSITION FOR PREVENTING AND TREATING MICROBIAL DISEASE - A composition for preventing and treating microbial diseases may include dimethyl sulfide (DMS); dimethyl sulfoxide (DMSO); and elemental sulfur. The composition may also include methylsulfonylmethane, water, surfactants, terpenes, terpenoids, thioterpenols, bronchodilators, and yield enhancers. A method for preventing and treating microbial disease, viruses, fungi, bacteria, and parasites may include administering a prophylactically or therapeutically effective dosage of the composition to a patient in need. | 2022-04-07 |
20220105127 | METHODS FOR PROVIDING THE BENEFITS OF METHIONINE RESTRICTION WITHOUT DIETARY RESTRICTION - A method of providing a methionine restriction benefit to a subject without restricting the subject's diet is provided. The method includes administering an effective amount of a pharmaceutical composition to the subject. The pharmaceutical composition includes one or more of a first compound and a selenium compound. The first compound includes at least one compound chosen from lysine, O-benzyl serine (OBS), S-phenyl cysteine (SPC), S-benzyl cysteine (SBC), isoleucine, taurine, tryptophan, and 2-aminobicyclo-(2.2.1)-heptane-2-carboxylic acid (BCH). The second compound includes at least one compound chosen from selenomethionine, selenohomocysteine, selenocystathionine, selenocysteine/selenocystine, selenoglutathione trisulfide, methaneselenol, dimethyl selenide, trimethyl selenide, purified selenomethionine, selenized yeast extract, and pharmaceutically-acceptable salts of selenium-based acids. | 2022-04-07 |